The satellite symposium at EHA2022 was chaired by Paolo Ghia joined by Federico Pea, Barbara Eichhorst, Shirley D’Sa and Ramón García Sanz. They discussed next-generation BTK inhibitors in the treatment of B-cell malignancies.
Oral presentation presented at EHA2022 describing the primary analysis of the phase 2 randomized ROSEWOOD trial: Zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refratory (R/R) follicular lymphoma (FL).
Report on targeted and immune-directed therapies in B-cell malignancies presented at ASCO, EHA and ICML 2021.
Report on recent developments in the treatment of B-cell malignancies presented at ASCO, EHA and ICML 2021.
Preliminary safety and efficacy data of the phase 1a/1b trial of BGB-11417 (BCL2 inhibitor) with or without zanubrutinib in patients with relapsed/refractory B cell malignancies.
